Design and Synthesis of Fragment Derivatives with a Unique Inhibition Mechanism of the uPAR·uPA Interaction
dc.contributor.author | Bum-Erdene, Khuchtumur | |
dc.contributor.author | Liu, Degang | |
dc.contributor.author | Xu, David | |
dc.contributor.author | Ghozayel, Mona K. | |
dc.contributor.author | Meroueh, Samy O. | |
dc.contributor.department | Biochemistry and Molecular Biology, School of Medicine | en_US |
dc.contributor.department | ||
dc.date.accessioned | 2023-04-20T13:52:21Z | |
dc.date.available | 2023-04-20T13:52:21Z | |
dc.date.issued | 2020 | |
dc.description.abstract | There is substantial interest in the development of small molecules that inhibit the tight and highly challenging protein-protein interaction between the glycophosphatidylinositol (GPI)-anchored cell surface receptor uPAR and the serine protease uPA. While preparing derivatives of a fragment-like compound that previously emerged from a computational screen, we identified compound 5 (IPR-3242), which inhibited binding of uPA to uPAR with submicromolar IC50s. The high inhibition potency prompted us to carry out studies to rule out potential aggregation, lack of stability, reactivity, and nonspecific inhibition. We designed and prepared 16 derivatives to further explore the role of each substituent. Interestingly, the compounds only partially inhibited binding of a fluorescently labeled α-helical peptide that binds to uPAR at the uPAR·uPA interface. Collectively, the results suggest that the compounds bind to uPAR outside of the uPAR·uPA interface, trapping the receptor into a conformation that is not able to bind to uPA. Additional studies will have to be carried out to determine whether this unique inhibition mechanism can occur at the cell surface. | en_US |
dc.eprint.version | Final published version | en_US |
dc.identifier.citation | Bum-Erdene K, Liu D, Xu D, Ghozayel MK, Meroueh SO. Design and Synthesis of Fragment Derivatives with a Unique Inhibition Mechanism of the uPAR·uPA Interaction. ACS Med Chem Lett. 2020;12(1):60-66. Published 2020 Dec 10. doi:10.1021/acsmedchemlett.0c00422 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/32531 | |
dc.language.iso | en_US | en_US |
dc.publisher | American Chemical Society | en_US |
dc.relation.isversionof | 10.1021/acsmedchemlett.0c00422 | en_US |
dc.relation.journal | ACS Medicinal Chemistry Letters | en_US |
dc.rights | Publisher Policy | en_US |
dc.source | PMC | en_US |
dc.subject | uPAR | en_US |
dc.subject | Urokinase plasminogen activator receptor | en_US |
dc.subject | Protein−protein interaction | en_US |
dc.subject | Small-molecule inhibitor | en_US |
dc.subject | Fragment-based drug design | en_US |
dc.title | Design and Synthesis of Fragment Derivatives with a Unique Inhibition Mechanism of the uPAR·uPA Interaction | en_US |
dc.type | Article | en_US |
ul.alternative.fulltext | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812671/ | en_US |